VanEck Associates’s Intellia Therapeutics NTLA Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $19K | Hold |
2,007
| – | – | ﹤0.01% | 1360 |
|
|
2025
Q1 | $14K | Sell |
2,007
-181
| -8% | -$1.26K | ﹤0.01% | 1352 |
|
|
2024
Q4 | $26K | Buy |
2,188
+594
| +37% | +$7.06K | ﹤0.01% | 1328 |
|
|
2024
Q3 | $32K | Sell |
1,594
-594
| -27% | -$11.9K | ﹤0.01% | 1295 |
|
|
2024
Q2 | $49K | Buy |
2,188
+85
| +4% | +$1.9K | ﹤0.01% | 1286 |
|
|
2024
Q1 | $58K | Buy |
2,103
+161
| +8% | +$4.44K | ﹤0.01% | 1273 |
|
|
2023
Q4 | $59K | Buy |
1,942
+327
| +20% | +$9.94K | ﹤0.01% | 1276 |
|
|
2023
Q3 | $51K | Sell |
1,615
-82,927
| -98% | -$2.62M | ﹤0.01% | 1282 |
|
|
2023
Q2 | $3.45M | Buy |
84,542
+731
| +0.9% | +$29.8K | 0.01% | 600 |
|
|
2023
Q1 | $3.12M | Sell |
83,811
-9,879
| -11% | -$368K | 0.01% | 596 |
|
|
2022
Q4 | $3.27M | Buy |
93,690
+30,589
| +48% | +$1.07M | 0.01% | 568 |
|
|
2022
Q3 | $3.53M | Sell |
63,101
-21,855
| -26% | -$1.22M | 0.01% | 518 |
|
|
2022
Q2 | $4.4M | Buy |
84,956
+6,728
| +9% | +$348K | 0.01% | 489 |
|
|
2022
Q1 | $5.69M | Sell |
78,228
-1,656
| -2% | -$120K | 0.01% | 479 |
|
|
2021
Q4 | $9.45M | Buy |
79,884
+13,010
| +19% | +$1.54M | 0.02% | 385 |
|
|
2021
Q3 | $8.97M | Buy |
+66,874
| New | +$8.97M | 0.02% | 359 |
|